Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a 'Buy' rating on AngioDynamics (NASDAQ:ANGO) and raises the price target from $18 to $20.
July 13, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on AngioDynamics and raises the price target from $18 to $20.
The news of Canaccord Genuity maintaining a 'Buy' rating and raising the price target for AngioDynamics is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100